06:18 AM EDT, 03/09/2026 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) reported a Q4 net loss Monday of $0.42 per diluted share.
Three analysts surveyed by FactSet expected a loss of $0.39.
Revenue for the quarter ended Dec. 31 was $28.1 million.
Analysts surveyed by FactSet expected revenue of $25.6 million.